243 related articles for article (PubMed ID: 21552290)
1. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.
Rajan N; Elliott R; Clewes O; Mackay A; Reis-Filho JS; Burn J; Langtry J; Sieber-Blum M; Lord CJ; Ashworth A
Oncogene; 2011 Oct; 30(41):4243-60. PubMed ID: 21552290
[TBL] [Abstract][Full Text] [Related]
2. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression.
Rajan N; Burn J; Langtry J; Sieber-Blum M; Lord CJ; Ashworth A
J Pathol; 2011 Jul; 224(3):309-21. PubMed ID: 21598248
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells.
Rajan N; Andersson MK; Sinclair N; Fehr A; Hodgson K; Lord CJ; Kazakov DV; Vanecek T; Ashworth A; Stenman G
J Pathol; 2016 Jun; 239(2):197-205. PubMed ID: 26969893
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours.
Leonard N; Chaggar R; Jones C; Takahashi M; Nikitopoulou A; Lakhani SR
J Clin Pathol; 2001 Sep; 54(9):689-92. PubMed ID: 11533075
[TBL] [Abstract][Full Text] [Related]
5. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
6. The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling.
Rajan N; Elliott RJ; Smith A; Sinclair N; Swift S; Lord CJ; Ashworth A
Oncotarget; 2014 Dec; 5(23):12126-40. PubMed ID: 25565632
[TBL] [Abstract][Full Text] [Related]
7. ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma.
Rashid M; van der Horst M; Mentzel T; Butera F; Ferreira I; Pance A; Rütten A; Luzar B; Marusic Z; de Saint Aubain N; Ko JS; Billings SD; Chen S; Abi Daoud M; Hewinson J; Louzada S; Harms PW; Cerretelli G; Robles-Espinoza CD; Patel RM; van der Weyden L; Bakal C; Hornick JL; Arends MJ; Brenn T; Adams DJ
Nat Commun; 2019 May; 10(1):2213. PubMed ID: 31101826
[TBL] [Abstract][Full Text] [Related]
8. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
9. CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma.
Williams EA; Montesion M; Sharaf R; Corines J; Patel PJ; Gillespie BJ; Pavlick DC; Sokol ES; Alexander BM; Williams KJ; Elvin JA; Ross JS; Ramkissoon SH; Hemmerich AC; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2614-2625. PubMed ID: 32461623
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous appendage tumors: familial cylindromatosis and associated tumors update.
Lian F; Cockerell CJ
Adv Dermatol; 2005; 21():217-34. PubMed ID: 16350444
[No Abstract] [Full Text] [Related]
11. Inherited cylindromas: lessons from a rare tumour.
Rajan N; Ashworth A
Lancet Oncol; 2015 Sep; 16(9):e460-e469. PubMed ID: 26370355
[TBL] [Abstract][Full Text] [Related]
12. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
13. Carcinoma ex spiradenoma/cylindroma confirmed by immunohistochemical and molecular loss-of-heterozygosity profiling.
Jukic DM; Drogowski LM; Davie JR
Am J Dermatopathol; 2009 Oct; 31(7):702-8. PubMed ID: 19684510
[TBL] [Abstract][Full Text] [Related]
14. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
15. Clinical, genetic and experimental studies of the Brooke-Spiegler (CYLD) skin tumor syndrome.
Andersson MK; Kölby L; Nilsson JA; Stenman G
J Plast Surg Hand Surg; 2019 Apr; 53(2):71-75. PubMed ID: 30676842
[TBL] [Abstract][Full Text] [Related]
16. [Brooke-Spiegler syndrome].
Garat H; Loche F; Gorguet B; Rumeau H; Lamant L; Bazex J
Ann Dermatol Venereol; 1999; 126(6-7):513-7. PubMed ID: 10495861
[TBL] [Abstract][Full Text] [Related]
17. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response.
Friedman CS; O'Donnell MA; Legarda-Addison D; Ng A; Cárdenas WB; Yount JS; Moran TM; Basler CF; Komuro A; Horvath CM; Xavier R; Ting AT
EMBO Rep; 2008 Sep; 9(9):930-6. PubMed ID: 18636086
[TBL] [Abstract][Full Text] [Related]
18. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
Jenner MW; Leone PE; Walker BA; Ross FM; Johnson DC; Gonzalez D; Chiecchio L; Dachs Cabanas E; Dagrada GP; Nightingale M; Protheroe RK; Stockley D; Else M; Dickens NJ; Cross NC; Davies FE; Morgan GJ
Blood; 2007 Nov; 110(9):3291-300. PubMed ID: 17609426
[TBL] [Abstract][Full Text] [Related]
19. The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas.
Perez-Pinera P; Hernandez T; García-Suárez O; de Carlos F; Germana A; Del Valle M; Astudillo A; Vega JA
Mol Cell Biochem; 2007 Jan; 295(1-2):19-26. PubMed ID: 16862449
[TBL] [Abstract][Full Text] [Related]
20. Dermal cylindromas (turban tumour) and eccrine spiradenomas in a patient with membranous basal cell adenoma of the parotid gland.
Ferrándiz C; Campo E; Baumann E
J Cutan Pathol; 1985 Feb; 12(1):72-9. PubMed ID: 2982934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
